Linked Life Data

9166162

Source:http://linkedlifedata.com/resource/pubmed/id/9166162

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1997-6-12
pubmed:abstractText
The objectives of this study were to assess (1) whether treatment with oral contraceptives, in comparison with medroxyprogesterone and placebo, improved bone mineral in women with hypothalamic amenorrhea and (2) whether treatment with medroxyprogesterone, in comparison with placebo, improved bone mineral in women with hypothalamic oligomenorrhea.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0002-9378
pubmed:author
pubmed:issnType
Print
pubmed:volume
176
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1017-25
pubmed:dateRevised
2007-11-14
pubmed:otherAbstract
PIP: The objectives of this study were to assess 1) whether treatment with oral contraceptives (OCs), in comparison with medroxyprogesterone and placebo, improved bone mineral content and density in women with hypothalamic amenorrhea and 2) whether treatment with medroxyprogesterone, in comparison with placebo, improved bone mineral content and density in women with hypothalamic oligomenorrhea. The study was a randomized, controlled clinical trial. 24 White women, aged 14-28 years, with hypothalamic amenorrhea or oligomenorrhea were prospectively enrolled for a 12-month intervention period. Amenorrheic subjects were randomized to receive OCs, medroxyprogesterone, or placebo. Oligomenorrheic subjects were randomized to receive medroxyprogesterone or placebo. Bone mineral content and density were measured by dual-energy x-ray absorptiometry at baseline and at 6 and 12 months. In amenorrheic subjects spine and total body bone mineral measurements at 12 months were greater in the OC group than in the medroxyprogesterone and placebo groups when baseline bone mineral measurements, body weight, and age were controlled for (p or= 0.05). There were no differences in hip bone mineral calcium and bone mineral density measurements at 12 months among the three groups. In oligomenorrheic subjects there was no detectable improvement in bone mineral content and density associated with medroxyprogesterone use. This study supports the hypothesis that OC use in women with hypothalamic amenorrhea will improve lumbar spine and total body bone mineral content and density.
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months.
pubmed:affiliation
General Clinical Research Center, Texas Children's Hospital, Houston, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial